Certainly ED or Erectile dysfunction is one talked about health issue that men majorly suffer through. Individuals having high cholesterol or high blood pressure are likely to develop ED more than those who are devoid of all these health conditions. Now there is a firm belief that people undergoing medication to treat cardiovascular risk factors are likely to develop ED, but a new study has concluded that the blood-pressure decreasing candesartan/HCTZ also the cholesterol-decreasing statins nowhere negatively influence erectile function. This particular report came out in the Canadian Journal of Cardiology. The lead investigator of the research Philip Joseph who is an MD also an honorable Assistant Professor of Medicine at McMaster University, Hamilton, Ontario, Canada, explained some truths that earlier the research proposed that the high blood pressure and cholesterol which are the cardiovascular risk factors, somewhere promote the risk of ED, however there is comparatively no potential research analyzing whether changing the risk factors can anyhow influence its growth.
Investigators were bent on assessing the consequences of statin that lowers cholesterol and in combination with pharmacologic blood pressure reduction also how it affects erectile function. However this is nothing but a Heart Outcomes Prevention Evaluation - 3 (HOPE-3) substudy which was unplanned controlled trial, where the effect of double placebo was compared against the candesartan/HCTZ upon 2x2 factorial randomized controlled trial also rosuvastatin was tested. These two medicines were tested separately also in combination. With the help of a questionnaire which is the International Index of Erectile Function [IIEF] erectile function was calculated. Right at the beginning there were 2,000 men and the average follow up years were 5.8 years. There were five domains relevant to ED were chief investigation was conducted for consistent four weeks.
When the study was going on, none of the treat group was seen to undergo any change in erectile function right at the moment they are compared with their corresponding placebo groups. None of the medicines candesartan/HCTZ ( blood pressure reduction) and statin ( cholesterol lowering) spotted change in erectile function. Hence this medicine intake nowhere is associated with ED development.
As Dr. Joseph stated that the study showed that the medicines to lower the cardiac risk factors do nothing to change the erectile function. Those who go through the symptoms of ED blame the negative impacts to the medication but reports as Dr. Joseph has confirmed that patients having ED have nothing to do with these medicines. In one of the accompanying editorial, G.B. John Mancini who is an MD, FACC, FRCPC also a Cardiology Professor in the Department of Medicine said that those patients having concerns or symptoms of ED are nowhere under the impact of statins or the combination of this drug with other angiotensin receptor blocker/thiazide. However they are required to be evaluated more broadly and directed in the safe use of phosphodiesterase-5 inhibitors when nitrates are unused. The recent study however gives strong motivation to develop confidence in terms of male sexual health thus decreasing the cardiovascular risk. Men over the age of 50 are more or less 40 percent affected with ED symptoms and this is more common in those men who are having cardiovascular risk factors.